New hope for lung cancer patients who've run out of options?
NCT ID NCT07374614
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with a specific type of advanced lung cancer (ALK-positive) that has gotten worse during or after treatment with the drug lorlatinib. Researchers want to see if a different drug, iruplinalkib, can help control the cancer for a longer time. About 20 adults will take part, and the study will track how long the cancer stays under control and any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?